Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

Administration (FDA) to include these data in the prescribing information in the U.S.

Pharmion is also developing a next generation product, oral Azacitidine, for the treatment of MDS and other cancers where demethylation can provide an anti-tumor effect. Oral Azacitidine is the subject of a Phase 1 multi-center, open label dose escalation trial that will assess the maximum tolerated dose, dose limiting toxicities and safety of a seven day, multi-cycle oral dosing regimen of oral Azacitidine in patients with MDS and AML. In addition, the trial will examine pharmacokinetics and pharmacodynamic effects of orally administered Azacitidine, as compared with parenteral Vidaza.

Pharmion will hold a conference call to discuss these results later this morning, August 2, at 9:00 a.m. ET. The conference call will be simultaneously webcast on the Company's web site at http://www.pharmion.com, and archived for future review. Dial-in numbers for the conference call for institutional investors and analysts are as follows: participants from the U.S. 866.314.5232, International participants 617.213.8052, passcode: 71992680.

About the Trial Design

This was the largest randomized study ever conducted in higher-risk MDS. The study was a multi-center, randomized, open-label, parallel-group, Phase 3 trial of subcutaneous (SC) Vidaza (administered at 75/mg/m2/day SC for seven consecutive days every 28 days) plus best supportive care versus CCR plus best supportive care for the treatment of MDS. CCR consisted of one of three physician selected regimens: best supportive care alone, low-dose cytarabine plus best supportive care or standard chemotherapy plus best supportive care. EPO and prophylactic G-CSF use was not permitted. The CCR represented standard of care within the territories where the trial was conducted. The study evaluated 358 higher-risk MDS patients at sites in the U.S., Europe and Australia. Patients
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PLYMOUTH MEETING, Pa. , Aug. 28, 2014 ... surgical community, patients, and media, both for the ... to patient safety. The quick deployment of surgical ... new technology are prompting facilities to evaluate their ... for the entire surgical team.    ...
(Date:8/28/2014)... 2014 Amgen (NASDAQ: AMGN ) ... (BLA) to the U.S. Food and Drug Administration (FDA) ... cholesterol. Evolocumab is an investigational fully human monoclonal antibody ... protein that reduces the liver,s ability to remove low-density ... 1 ­ The BLA ...
(Date:8/28/2014)... ALISO VIEJO , Kalifornien, 28. ... Inc., hat heute den Start der ... Investigational Device Exemption, Forschungsausnahmegenehmigung) zur Beurteilung ... Systems zur Embolisation von Aneurysmen („WEB") ... University of Tennessee, Department of Neurosurgery/Semmes-Murphey ...
Breaking Medicine Technology:Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3
(Date:8/28/2014)... vaccine to prevent Ebola virus disease will begin next ... Diseases (NIAID), part of the National Institutes of Health. ... of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) ... to generate an immune system response in healthy adults. ... in Bethesda, Maryland. , The study is the first ...
(Date:8/28/2014)... 70 and over who identify themselves as ,old, feel ... perceive they have lower value than younger age groups. ... Kent, titled ,Being old and ill, across different countries: ... used data from the European Social Survey. Respondents, who ... self-rate their health., The researchers found that those living ...
(Date:8/28/2014)... August 28, 2014 Vaccine market - ... great interest among other healthcare industry sectors and sub-circles ... demand in vaccine with respect to evolving and spreading ... due to an improved understanding for a well-balanced life ... States. It has led to new opportunities for manufacturing ...
(Date:8/28/2014)... TX (PRWEB) August 28, 2014 After ... Dr. Paul Vitenas is excited to announce the ... of its kind in any city, Mirror Mirror Beauty ... building. , Situated on the corner of Richmond and ... modern architecture, luxurious amenities, and cutting-edge technology in a ...
(Date:8/28/2014)... Steven Reinberg HealthDay ... Treating pre-cancerous skin spots with a type of light therapy ... the lesions with liquid nitrogen, a new study suggests. ... the scalp and face of people with fair complexions who,ve ... of prior research found that people who underwent the light ...
Breaking Medicine News(10 mins):Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 3
... ... Hearing Institute (BHI) is urging families across America to make 2010 the year ... in response to new data that underscores the influence family members have in ... of nearly 47,000 households, more than half (51%) of new first-time owners of ...
... ... home top honors in American Spa Magazine,s 2009 Professional,s Choice Award in the Favorite ... ... 8, 2009 -- Oakworks® Inc., the premier U.S. manufacturer of wellness, spa, massage and ...
... , PHOENIX, Dec. 7 To standing cheers, ... (NNU) today unanimously endorsed the creation of the largest union ... and projected a major escalation in campaigns to expand union ... , "The promise of the future has arrived," said Karen ...
... Calif., Dec. 7 Patriot Scientific Corporation (OTC Bulletin ... its Board of Directors and will serve as chair ... 16 years of experience working in the software development ... and the delivery of consulting services for Cognizant Technology ...
... , LOS ANGELES, Dec. 7 Steeped in ... on Crystal Cruises, April 26 "Mind, Body and Spirit" ... the spiritual heritage of the region via personal meetings with ... meditation center, while guest health experts share insights on life ...
... , Department of Health Reminds At-Risk Pennsylvanians to ... federal Centers for Disease Control and Prevention, or CDC, ... flu vaccine to Pennsylvania to date, the state Department ... been distributed to 1,639 certified providers including pediatricians, family ...
Cached Medicine News:Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 2Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 3Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 4Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:Unanimous Vote Creates Largest RN Union in U.S. History 2Health News:Patriot Scientific Corporation Announces New Director 2Health News:Wellness Cruise Offers Crystal Guests 'Indian Ocean Insight' 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: